Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine.

Franceschi, J; Darrigade, A S; Sanchez-Pena, P; Legrain-Lifermann, V; Milpied, B

Franceschi, J; Darrigade, A S; Sanchez-Pena, P; Legrain-Lifermann, V; Milpied, B.

Afiliação

Franceschi J; Department of Dermatology, Bordeaux University Hospital, Bordeaux cedex, France.
Darrigade AS; Department of Dermatology, Bordeaux University Hospital, Bordeaux cedex, France.
Sanchez-Pena P; Regional Center of Pharmacovigilance, Pharmacology Department, Bordeaux University Hospital, Bordeaux cedex, France.
Legrain-Lifermann V; Department of Dermatology, Dax Hospital, Dax, France.
Milpied B; Department of Dermatology, Bordeaux University Hospital, Bordeaux cedex, France.

J Eur Acad Dermatol Venereol ; 36(12): e969-e970, 2022 12.

Article em En | MEDLINE | ID: mdl-35771124

Assuntos

COVID-19; Pioderma Gangrenoso; Humanos; Pioderma Gangrenoso/etiologia; Vacinas contra COVID-19/efeitos adversos; RNA Mensageiro; COVID-19/prevenção & controle; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Pioderma Gangrenoso / COVID-19 Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google